Min Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Min Shen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jiandong Wang
School of Pharmacy, Bengbu Medical College, 2600 Donghai Road, Bengbu 233030, China
1 shared publication - Junxia Yu
School of Pharmacy, Bengbu Medical College, 2600 Donghai Road, Bengbu 233030, China
1 shared publication - Quangang Zhu
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Tingting Cheng
School of Pharmacy, Bengbu Medical College, 2600 Donghai Road, Bengbu 233030, China
1 shared publication - Ying Li
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China
1 shared publication - Zhongjian Chen
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 21 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2165
Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System
Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, the effectiveness of the TDDS is hindered by several factors, including the barrier properties of the stratum corneum, the nature of the drug and carrier, and delivery conditions. In this paper, we provide an overview of the development of the TDDS from first-generation to fourth-generation systems, highlighting the characteristics of each carrier in terms of mechanism composition, penetration method, mechanism of action, and recent preclinical studies. We further investigated the significant challenges encountered in the development of the TDDS and the crucial significance of clinical trials.
- 21 August 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2165
Open AccessAdvance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System
Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, the effectiveness of the TDDS is hindered by several factors, including the barrier properties of the stratum corneum, the nature of the drug and carrier, and delivery conditions. In this paper, we provide an overview of the development of the TDDS from first-generation to fourth-generation systems, highlighting the characteristics of each carrier in terms of mechanism composition, penetration method, mechanism of action, and recent preclinical studies. We further investigated the significant challenges encountered in the development of the TDDS and the crucial significance of clinical trials.